Prevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj

Abstract

Background: Factor VIII inhibitor is one of the most problems in the treatment of hemophilia. Patients with hemophilia who have inhibitors are capable of severe hemorrhage and treatments of these patients are more expensive and more difficult than those patients without inhibitor. The aim of present study was to determine the prevalence of inhibitor and to assess the necessity of screening of the factor VIII inhibitors in hemophilia patients.